Assessment of vaginal atrophy: a review

International Urogynecology Journal

Volumn 26, Issue 1, 2015, Pages 15-28

  Weber, M A ^a   Limpens, J ^a   Roovers, J P W R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Definition; Diagnosis; Objective; Subjective; Symptoms; Vaginal atrophy

Indexed keywords

ATROPHY; FEMALE; HUMAN; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VAGINA; VAGINAL DISEASES;

ATROPHY; FEMALE; HUMANS; SEVERITY OF ILLNESS INDEX; VAGINA; VAGINAL DISEASES;

EID: 84939892252     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-014-2464-0     Document Type: Review

References (95)

1. Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61(10):3090–3096
2. Levine KB, Williams RE, Hartmann KE (2008) Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15(4 Pt 1):661–666
3. Nappi RE, Kokot-Kierepa M (2010) Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67(3):233–238
4. Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6(8):2133–2142
5. Stika CS (2010) Atrophic vaginitis. Dermatol Ther 23(5):514–522
6. Sturdee DW, Panay N, International Menopause Society Writing Group (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6):509–522
7. Archer DF (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17(1):194–203
8. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry (2003) Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation
9. US Department of Health an Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry (2006) Patient-reported outcome measures: use in medical product development to support labeling claims
10. Terwee CB, Jansma EP, Riphagen II, de Vet HC (2009) Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res 18(8):1115–1123
11. Chollet JA, Carter G, Meyn LA, Mermelstein F, Balk JL (2009) Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause 16(5):978–983
12. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD (2005) Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52(Suppl 1):S46–S52
13. Brenner PF (1988) The menopausal syndrome. Obstet Gynecol 72(5 Suppl):6S–11S
14. Nyirjesy P, Leigh RD, Mathew L, Lev-Sagie A, Culhane JF (2012) Chronic vulvovaginitis in women older than 50 years: analysis of a prospective database. J Low Genit Tract Dis 16(1):24–29
15. Greendale GA, Zibecchi L, Petersen L, Ouslander JG, Kahn B, Ganz PA (1999) Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climacteric 2(3):197–204
16. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M (2008) Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 111(1):67–76
17. Karaosmanoglu O, Cogendez E, Sozen H, Asoglu MR, Akdemir Y, Eren S (2011) Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis. Int J Gynaecol Obstet 113(2):156–157
18. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS (2000) 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7(3):156–161
19. Lynch C (2009) Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt) 18(10):1595–1606
20. Crothers BA, Booth CN, Darragh TM, Means MM, Souers RJ, Thomas N, Moriarty AT (2012) Atrophic vaginitis: concordance and interpretation of slides in the College of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology. Arch Pathol Lab Med 136(11):1332–1338
21. Capewell AE, McIntyre MA, Elton RA (1992) Post-menopausal atrophy in elderly women: is a vaginal smear necessary for diagnosis? Age Ageing 21(2):117–120
22. Yildirim B, Kaleli B, Düzcan E, Topuz O (2004) The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas 49(4):334–337
23. Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, Koenig D, Gloor GB, Reid G (2011) Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 6(11):e26602
24. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F (2005) Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 50(2):98–104
25. Bachmann GA, Komi JO, Ospemifene Study Group (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17(3):480–486
26. Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23(3):259–263
27. Manonai J, Chittacharoen A, Theppisai U, Theppisai H (2007) Effect of Pueraria mirifica on vaginal health. Menopause 14(5):919–924
28. Simunić V, Banović I, Ciglar S, Jeren L, Pavicić Baldani D, Sprem M (2003) Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 82(2):187–197
29. Rane A, Hassan S, Corstiaans A (2000) Does conventional HRT protect from urogenital atrophy? A prospective study. J Obstet Gynaecol 20(3):306–307
30. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH (2010) A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17(2):281–289
31. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W (2008) Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. [Erratum appears in Obstet Gynecol 2008 Dec;112(6):1392]. Obstet Gynecol 112(5):1053–1060
32. Chollet JA (2011) Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence 5:571–574
33. Le Donne M, Caruso C, Mancuso A, Costa G, Iemmo R, Pizzimenti G, Cavallari V (2011) The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 283(6):1319–1323
34. Al-Baghdadi O, Ewies AA (2009) Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12(2):91–105
35. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Castellanos E, Moral E, Nieto C, del Prado JM, Ferrer J (2012) The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005 % estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 19(10):1130–1139
36. Minkin MJ, Maamari R, Reiter S (2013) Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health 5:133–139
37. Pandit L, Ouslander JG (1997) Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 314(4):228–231
38. van der Laak JA, Schijf CP, Kerstens HM, Heijnen-Wijnen TH, de Wilde PC, Hanselaar GJ (1999) Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. Cytometry 35(3):196–202
39. McEndree B (1999) Clinical application of the vaginal maturation index. Nurse Pract 24(9):48–56
40. Simon JA, Reape KZ, Wininger S, Hait H (2008) Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 90(4):1132–1138
41. Barentsen R, van de Weijer PH, Schram JH (1997) Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 71(1):73–80
42. Casper F, Petri E (1999) Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 10(3):171–176
43. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I (1996) A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174(1 Pt 1):85–92
44. Speroff L (2003) Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102(4):823–834
45. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I (1994) A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 171(3):624–632
46. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Fraser ID (1996) A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 103(4):351–358
47. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 117(4):922–927
48. Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E (2007) The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil Steril 88(2):530–532
49. Speroff L, Haney AF, Gilbert RD, Ellman H, Estradiol Acetate Investigator Group (2006) Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause 13(3):442–450
50. Utian WH, Speroff L, Ellman H, Dart C (2005) Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause 12(6):708–715
51. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, Kivanҫ E (2011) The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 283(3):539–543
52. Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S (2003) Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 10(1):45–52
53. Meisels A (1967) The maturation value. Acta Cytol 11:249
54. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A (2010) A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 7(3):1284–1290
55. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H (2009) Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 16(4):735–741
56. Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S (2006) The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. Maturitas 54(2):135–140
57. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M (2012) Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 71(4):360–368
58. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC (2007) Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 109(3):588–596
59. Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S, Seiler J, Kopka SL (2003) Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 188(2):382–388
60. Karp DR, Jean-Michel M, Johnston Y, Suciu G, Aguilar VC, Davila GW (2012) A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Med Reconstr Surg 18(4):211–215
61. Smith P, Heimer G, Lindskog M, Ulmsten U (1993) Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16(2):145–154
62. Nilsson K, Risberg B, Heimer G (1995) The vaginal epithelium in the postmenopause–cytology, histology and pH as methods of assessment. Maturitas 21(1):51–56
63. Yumru AE, Bozkurt M, Inci Coşkun E, Baykan G (2009) The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency. J Int Med Res 37(1):198–204
64. Benjamin F, Deutsch S (1980) Immunoreactive plasma estrogens and vaginal hormone cytology in postmenopausal women. Int J Gynaecol Obstet 17(6):546–550
65. Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, Graepel J, Helzner E (2009) Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 16(4):719–727
66. Schaffer J, Fantl JA (1996) Urogenital effects of the menopause. Baillieres Clin Obstet Gynaecol 10(3):401–417
67. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S (2012) Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 285(2):397–403
68. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, Marci R, Cosmi E (2004) Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11(1):49–56
69. Mishell D (1987) Menopause: physiology and pharmacology. Yearbook, Chicago
70. Wied G, Bibbo M (1975) Evaluation of endocrinologic condition by exfoliative cytology. In: Gold JJ (ed) Textbook of gynaecologic endocrinology. Harper and Row, New York
71. Milsom I, Arvidsson L, Ekelund P, Molander U, Eriksson O (1993) Factors influencing vaginal cytology, pH and bacterial flora in elderly women. Acta Obstet Gynecol Scand 72(4):286–291
72. Caillouette J, Sharp C, Zimmerman G, Roy S (1997) Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 176:1270–1275
73. Roy S, Caillouette J, Roy T, Faden J (2004) Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol 190:1272–1277
74. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16(5):907–922
75. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A (2001) The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 27(5):255–260
76. Bachmann GA, Schaefers M, Uddin A, Utian WH (2009) Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause 16(5):877–882
77. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr, Study Groups on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream (2003) Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 101(2):346–352
78. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26(6):404–412
79. Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2011) Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 14(2):282–288
80. Brizzolara S, Killeen J, Severino R (1999) Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol 94:700–703
81. Ettinger B, Hait H, Reape KZ, Shu H (2008) Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 15(5):885–889
82. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Martel C, Balser J (2010) High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol 26(7):524–532
83. Eriksen B (1999) A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180(5):1072–1079
84. Eriksen PS, Rasmussen H (1992) Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 44(2):137–144
85. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM (2006) Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 13(6):917–925
86. McKenna SP, Whalley D, Renck-Hooper U, Carlin S, Doward LC (1999) The development of a quality of life instrument for use with post-menopausal women with urogenital atrophy in the UK and Sweden. Qual Life Res 8(5):393–398
87. Lester J, Bernhard L, Ryan-Wenger N (2012) A self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors. West J Nurs Res 34(1):72–96
88. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O’Neill S, Kirkegard Y, Fraser IS (2005) Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8(1):83–92
89. Bachmann G (1994) Vulvo-vaginal complaints. In: Lobo R (ed.) Treatment of the postmenopausal woman. Raven, New York
90. Raymundo N, Yu-cheng B, Zi-yan H, Lai CH, Leung K, Subramaniam R, Bin-rong C, Ling YS, Nasri N, Calimon N (2004) Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 7(3):312–318
91. Laan E, van Lunsen RH (1997) Hormones and sexuality in postmenopausal women: a psychophysiological study. J Psychosom Obstet Gynaecol 18(2):126–133
92. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L (1983) Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 249(16):2195–2198
93. Nappi RE, Kokot-Kierepa M (2012) Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric 15(1):36–44
94. van Geelen JM, van de Weijer PH, Arnolds HT (2000) Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct 11(1):9–14
95. Pastore LM, Carter RA, Hulka BS, Wells E (2004) Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas 49(4):292–303